ADC THERAPEUTICS SA (ADCT)
ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalin
CS Hotline: +852 3018 4526
Trading days: 24 hours | Non-trading days: 9:00-18:00
